Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 13/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3021060 | 0.94 | FAAH (0.59) | FAAHCYP3A4CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL14934449 | 0.88 | EPHX2 (0.65) | — | |
| SCHEMBL14934441 | 0.84 | FAAH (0.63) | FAAHCYP3A4CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL896470 | 0.80 | FAAH (1.00) | FAAH | |
| SCHEMBL14934576 | 0.79 | FAAH (0.67) | FAAHCYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL15170980 | 0.78 | ALDH1A1 (0.49) | FAAHCYP3A4CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL896545 | 0.78 | FAAH (0.93) | FAAH | |
| SCHEMBL4692167 | 0.78 | CYP2D6 (0.70) | CYP3A4CYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL3026001 | 0.78 | FAAH (0.67) | FAAH | |
| SCHEMBL2791789 | 0.77 | CCR8 (0.69) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013065712-A1 | DIAZASPIROUREA DERIVATIVE AND PHARMACEUTICAL USE THEREOF | 東レ株式会社 (JP) | 2013-05-10 | — | — | WO | disclosed |
| US-20100204224-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS | VERNALIS R & D LIMITED (GB) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204224-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS | SCN1B, SCN2B, SCN1A | FAAH 597/4885CYP3A4 2928/4885CYP1A2 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.